ID
11709
Description
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart attack), repeat myocardial infarctions, stroke, and ischemia (inadequate blood supply to a local area) in patients with recent ACS. https://clinicaltrials.gov/ct2/show/NCT00402597
Link
https://clinicaltrials.gov/ct2/show/NCT00402597
Keywords
Versions (1)
- 7/28/15 7/28/15 -
Uploaded on
July 28, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility ATLAS ACS TIMI 46 Acute Coronary Syndrome NCT00402597
Eligibility criteria
- StudyEvent: ODM
Description
Exclusion Criteria
Description
Active bleeding
Data type
boolean
Alias
- UMLS CUI-1
- C0019080
Description
risk of bleeding
Data type
boolean
Alias
- UMLS CUI-1
- C3251812
Description
intracranial hemorrhage
Data type
boolean
Alias
- UMLS CUI-1
- C0151699
Description
anticoagulant therapy
Data type
boolean
Alias
- UMLS CUI-1
- C0150457
Description
Significantly impaired renal function
Data type
boolean
Alias
- UMLS CUI-1
- C0035078
Description
Significantly impaired hepatic function
Data type
boolean
Alias
- UMLS CUI-1
- C0085605
Description
cardiogenic shock
Data type
boolean
Alias
- UMLS CUI-1
- C0036980
Description
ventricular arrhythmias
Data type
boolean
Alias
- UMLS CUI-1
- C0085612
Similar models
Eligibility criteria
- StudyEvent: ODM